Cyclosporine: clinical application and production overview of immunosuppressants

Cyclosporine is an immunosuppressant widely used in organ transplantation and the treatment of autoimmune diseases. It works by selectively inhibiting T cell activity. This article will focus on four aspects: its mechanism of action, indications, medication precautions and major manufacturers to help readers fully understand this key drug. Among them,Indications and safety managementas core content, and production information as auxiliary reference.

Mechanism of action and core indications

Cyclosporine blocks the calcineurin pathway and inhibits the release of interleukin-2 (IL-2) by T cells, thereby reducing the immune response. itsMain indicationsIncluding: anti-rejection after organ transplantation (such as kidney, liver, heart transplantation), severe rheumatoid arthritis, psoriasis and aplastic anemia, etc. Clinical data show that cyclosporine can reduce the incidence of acute rejection to less than 20% (data source: "New England Journal of Medicine").

Medication precautions and adverse reactions

Cyclosporine blood concentration needs to be strictly monitored, as overdose may lead toIncreased risk of nephrotoxicity, hypertension, or infection. It is recommended to check kidney function, blood pressure and blood potassium levels regularly. Common adverse reactions include hirsutism, gingival hyperplasia, and gastrointestinal discomfort. When combined with drugs such as ketoconazole, the blood concentration will increase, and the dose needs to be adjusted (reference: US FDA drug instructions).

Main manufacturers and product information

Summary and clinical value

As a landmark drug in immunosuppressive therapy, cyclosporine has significantly improved the survival rate of transplanted organs, but it needs to balance efficacy and safety. Physicians should adjust dosage according to individual patient conditions and pay attention to drug interactions. Standardized production at home and abroad ensures the accessibility of medicines, but patients need to use them under professional guidance.

Quote sources:

1. "New England Journal of Medicine": Clinical study of cyclosporine in renal transplantation, 1984
2. U.S. FDA Drug Insert: Cyclosporine Safety Information
3. National Medical Products Administration: Approved list of cyclosporine preparations